HR and breast cancer: This phase I/IIa study evaluated the safety, PK, pharmacodynamics, and preliminary antitumor activity of the first-in-class CDK2/4/6i PF-06873600, alone and in combination with ET, in patients with HR+/HER2− advanced breast cancer or mBC.